A for Breast Cancer

Phase-Based Progress Estimates
University of Rochester Medical Center, Rochester, NYBreast Cancer+3 MoreTrastuzumab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing neratinib, an aromatase inhibitor, and trastuzumab as a treatment for breast cancer.

Eligible Conditions
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Estrogen Receptor-positive Breast Cancer
  • Triple-Positive Breast Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: 24 weeks

24 weeks
Assess Adverse Events
Disease Free Survival (DFS)
Measure Residual Disease
Overall Survival (OS)
Pathologic Complete Response (pCR)
Pathological Complete Response (pCR)
Radiologic Response

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

48 Total Participants · 1 Treatment Group

Primary Treatment: A · No Placebo Group · Phase 2

AExperimental Group · 3 Interventions: Trastuzumab, Neratinib, Letrozole (L) or Anastrozole (A) · Intervention Types: Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 weeks

Who is running the clinical trial?

Puma Biotechnology, Inc.Industry Sponsor
52 Previous Clinical Trials
9,621 Total Patients Enrolled
13 Trials studying Breast Cancer
4,349 Patients Enrolled for Breast Cancer
Ruth O'ReganLead Sponsor
University of RochesterOTHER
799 Previous Clinical Trials
505,820 Total Patients Enrolled
11 Trials studying Breast Cancer
1,686 Patients Enrolled for Breast Cancer
Ruth O'Regan, MDPrincipal InvestigatorUniversity of Rochester
4 Previous Clinical Trials
169 Total Patients Enrolled
2 Trials studying Breast Cancer
32 Patients Enrolled for Breast Cancer

Eligibility Criteria

Age 18+ · All Participants · 19 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing to have another breast tissue sample taken 3 weeks after starting treatment.
You have invasive breast cancer that is in stages I, II or III and your tumor is larger than 10mm.

Frequently Asked Questions

For what purpose is A commonly prescribed?

"A is a viable option for managing brca1 gene-related issues, including breast cancer and inflammatory breast cancer (IBC). Additionally, 2 to 3 years of tamoxifen therapy can be utilized in tandem with A." - Anonymous Online Contributor

Unverified Answer

Could you provide an account of other experiments conducted with A?

"Presently, there are 362 active clinical trials researching A with 91 of those studies being in Phase 3. These investigations are primarily taking place in Seattle, Washington; however, there is a total of 26633 sites conducting research related to this topic." - Anonymous Online Contributor

Unverified Answer

Does this research endeavor still accept participants?

"According to clinicaltrials.gov, recruitment for this medical trial is still ongoing. The research project was first uploaded on the 21st of July 2022 and underwent its last modification on the 10th of October 2022." - Anonymous Online Contributor

Unverified Answer

Are there any known dangers associated with utilizing A?

"This Phase 2 trial has not yet yielded efficacy data, thus our team at Power gave a safety rating of 2 for medication A." - Anonymous Online Contributor

Unverified Answer

How many participants are currently undergoing treatment in this clinical trial?

"Affirmative. According to clinicaltrials.gov, this research is still in the process of recruiting participants for its trials which first began on July 21st 2022 and was most recently revised on October 10th 2022. 48 patients are needed from 1 single medical site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.